Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BARDA Extends Deadline for Pandemic Influenza Vaccine Proposals

by Stephanie Lizotte
March 18, 2012

The Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services (HSS), has extended the deadline for vaccine companies to submit proposals for Pandemic Influenza Medical Countermeasures under Solicitation 11-100-SOL-00020. The new cut-off date is April 20, 2012.

The BARDA Strategic Plan 2011-2016 calls for enhanced development and procurement of countermeasures for pandemic influenza preparedness and response. This resultant Request for Proposal (RFP) is open to companies that currently produce inactivated, recombinant and Live Attenuated Influenza Vaccine (LAIV), seasonal, pre-pandemic and pandemic influenza vaccine at commercial scale.

Included in a comprehensive list of RFP requirements are: master and working virus seed for production of influenza pre-pandemic and pandemic vaccine product; production at small scale, clinical and commercial scale of influenza pre-pandemic and pandemic vaccine and adjuvant; non-clinical and clinical studies using pre-pandemic and pandemic influenza vaccine; storage and shipping shipping services; and vaccine and adjuvant stability studies.

BARDA has estimated an award on this competition to be announced in August 2012, with the possibility of multiple awards. The anticipated period of performance will be for a total of up to five years with the potential for two additional year-long option periods.

Tags: ASPRBARDAHHSInfluenzaPandemicRequest for ProposalsVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC